Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should

Benzer Materyaller

• NOTES: because we can or because we should?
  Yazar:: Chand, Manish, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
  Yazar:: McGraw, K L, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
  Yazar:: Montalban-Bravo, Guillermo, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
  Yazar:: Takahashi, Koichi, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
  Yazar:: Sallman, David A., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)